[go: up one dir, main page]

CN116637088A - Ambroxol hydrochloride sustained-release particles and preparation method thereof - Google Patents

Ambroxol hydrochloride sustained-release particles and preparation method thereof Download PDF

Info

Publication number
CN116637088A
CN116637088A CN202310648680.7A CN202310648680A CN116637088A CN 116637088 A CN116637088 A CN 116637088A CN 202310648680 A CN202310648680 A CN 202310648680A CN 116637088 A CN116637088 A CN 116637088A
Authority
CN
China
Prior art keywords
parts
ambroxol hydrochloride
release
sustained
slow
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202310648680.7A
Other languages
Chinese (zh)
Inventor
狄会峰
韩静
刘会
徐淑娜
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ji'nan People's Hospital
Original Assignee
Ji'nan People's Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ji'nan People's Hospital filed Critical Ji'nan People's Hospital
Priority to CN202310648680.7A priority Critical patent/CN116637088A/en
Publication of CN116637088A publication Critical patent/CN116637088A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The application belongs to the field of pharmaceutical preparations, and relates to ambroxol hydrochloride sustained-release particles and a preparation method thereof. The ambroxol hydrochloride slow-release particles comprise the following components: 20-50 parts of ambroxol hydrochloride, 6-30 parts of a flavoring agent, 60-100 parts of cyclodextrin, 50-100 parts of sodium alginate, 30-80 parts of chitosan, 10-80 parts of a slow release material, 10-50 parts of a pore-forming agent and 3-20 parts of an adhesive. The ambroxol hydrochloride slow release particles provided by the application have gentle dissolution, can realize stable release within 10 hours, have no burst release phenomenon, can better mask the bitter taste of ambroxol hydrochloride, are convenient to take, and have better tolerance to children patients and adult patients with dysphagia.

Description

Ambroxol hydrochloride sustained-release particles and preparation method thereof
Technical Field
The application belongs to the field of pharmaceutical preparations, and relates to ambroxol hydrochloride sustained-release particles and a preparation method thereof.
Background
Ambroxol hydrochloride can promote the removal of viscous secretion in the respiratory tract and reduce the retention of mucus, thereby obviously promoting sputum excretion. Is suitable for acute and chronic respiratory diseases accompanied with abnormal sputum secretion and poor sputum excretion, is the expectorant with strongest clinical effect at present, and has remarkable curative effect.
Ambroxol hydrochloride has extremely strong bitter taste, and limits the application of ambroxol hydrochloride in the aspect of children medication. Taste masking is a technical problem that needs to be broken through in the preparation of syrup, granules and other preparations for children. In the prior art, a large amount of corrigents, sweeteners and syrups are added to cover the peculiar smell of the medicine, but the mode can not cover the peculiar smell of the medicine completely, and for the granule, the addition of a large amount of sweeteners and the like is easy to cause the granule to absorb moisture and agglomerate, so that the medicine effect is reduced.
The half-life period of ambroxol hydrochloride in a human body is short, and common oral quick-release preparations such as ambroxol hydrochloride oral liquid, ambroxol hydrochloride tablets and the like which are on the market at present can realize stable and effective blood concentration only by being administrated 2-3 times per day. The commercial oral sustained release tablet and sustained release capsule can meet the daily medication requirement of adults, but the preparation has larger size and is not suitable for children and adult patients with dysphagia, so that the development of a sustained release preparation convenient for swallowing is very necessary.
Disclosure of Invention
In order to overcome the defects in the prior art, the application provides ambroxol hydrochloride sustained-release particles which are convenient for children and adults with dysphagia to take, have few administration times and can be released stably and a preparation method thereof.
The application adopts the following technical scheme to realize the above.
The ambroxol hydrochloride sustained-release particles are prepared by the following method:
step A, adding a flavoring agent into cyclodextrin for grinding, then adding ambroxol hydrochloride, grinding, drying, and washing with an organic solvent to obtain an inclusion compound for later use;
b, adding the inclusion compound obtained in the step A into a sodium alginate-chitosan solution in a molten state, and drying to obtain a medicine core for standby;
and C, preparing a slow-release coating liquid from the slow-release material and Kong Jijia ethanol, spraying the slow-release coating liquid on the surface of the drug core obtained in the step B, drying, adding an adhesive, and granulating to obtain ambroxol hydrochloride slow-release particles.
The ambroxol hydrochloride slow release particles comprise the following components in percentage by weight:
ambroxol hydrochloride 20-50 parts
6-30 parts of flavoring agent
Cyclodextrin 60-100 parts
50-100 parts of sodium alginate
30-80 parts of chitosan
10-80 parts of slow-release material
10-50 parts of pore-forming agent
3-20 parts of adhesive
Further, the ambroxol hydrochloride sustained-release particles comprise the following components in percentage by weight:
ambroxol hydrochloride 20-50 parts
12-23 parts of flavoring agent
Cyclodextrin 65-80 parts
60-80 parts of sodium alginate
Chitosan 50-60 parts
30-50 parts of slow release material
20-35 parts of pore-forming agent
9-14 parts of adhesive
Specifically, the flavoring agent in the above components is selected from one or more of stevioside, aspartame, sodium cyclamate, sucralose, xylitol, peppermint essence, strawberry essence, lemon essence, hami melon essence, vanillin, etc.; the cyclodextrin is selected from one or more of hydroxypropyl-beta-cyclodextrin, methyl-beta-cyclodextrin, alpha-cyclodextrin and the like; the slow release material is selected from one or a combination of more of sodium carboxymethyl cellulose, methyl cellulose, hydroxypropyl methylcellulose, povidone, acrylic resin and the like; the pore-forming agent is selected from one or more of lactose, mannitol, sucrose, xylitol and the like; the binder is selected from one or more of starch slurry, maltose syrup, methylcellulose, sodium carboxymethylcellulose, low-substituted hydroxypropyl cellulose, hydroxypropyl methylcellulose, ethyl cellulose, polyvinylpyrrolidone, etc.
Further, the flavoring agent in the components comprises 2-10 parts of stevioside, 1-8 parts of sucralose and 3-12 parts of strawberry essence; the cyclodextrin is hydroxypropyl-beta-cyclodextrin; the slow release material contains 2-35 parts of sodium carboxymethyl cellulose and 8-45 parts of acrylic resin; the pore-forming agent is lactose; the adhesive contains 1-12 parts of low-substituted hydroxypropyl cellulose and 2-8 parts of polyvinylpyrrolidone.
Further preferably, the flavoring agent comprises 4-8 parts of stevioside, 3-5 parts of sucralose and 5-10 parts of strawberry essence; the slow release material comprises 14-23 parts of sodium carboxymethyl cellulose and 16-27 parts of acrylic resin; the adhesive contains 5-8 parts of low-substituted hydroxypropyl cellulose and 4-6 parts of polyvinylpyrrolidone.
The application has the following beneficial effects:
the ambroxol hydrochloride slow release particles are prepared by the method, wherein the ambroxol hydrochloride slow release particles are prepared by the method, and the ambroxol hydrochloride slow release particles are prepared by the method, wherein the ambroxol hydrochloride slow release particles are prepared by the method, and the ambroxol hydrochloride slow release particles can be prepared by the method, after the ambroxol hydrochloride slow release particles are subjected to an acceleration test, the ambroxol hydrochloride bitter taste can be effectively covered, and have good acceptability for children patients; meanwhile, the problems of moisture absorption, caking and the like of the granules can be improved, and the drug effect is maintained.
The ambroxol hydrochloride sustained-release granule provided by the application can realize stable release within 10 hours, can reduce the times of drug administration, and is convenient for children and adult patients with dysphagia.
DETAILED DESCRIPTION OF EMBODIMENT (S) OF INVENTION
The present application is further illustrated below with reference to specific examples, which are to be construed as merely illustrative of the application and not limiting of its scope, as various equivalent modifications to the application will fall within the scope of the claims after reading the application.
EXAMPLE 1 preparation of ambroxol hydrochloride sustained-release particles
The preparation method comprises the following steps: adding appropriate amount of water into hydroxypropyl-beta-cyclodextrin, grinding, adding correctant (stevioside, sucralose, strawberry essence), grinding, mixing, adding ambroxol hydrochloride, grinding, mixing, drying at low temperature, washing with absolute ethanol, and drying to obtain clathrate; mixing sodium alginate and chitosan in prescribed amount, heating to molten state, adding clathrate into molten sodium alginate-chitosan liquid, mixing, and drying to obtain medicated core; adding water into sustained release material (sodium carboxymethylcellulose, acrylic acid resin) and pore-forming agent (lactose) to obtain sustained release coating liquid, spraying on the surface of the drug core, drying, adding adhesive (low substituted hydroxypropyl cellulose and polyvinylpyrrolidone), granulating, and drying to obtain ambroxol hydrochloride sustained release granule.
EXAMPLE 2 preparation of ambroxol hydrochloride sustained-release particles
The preparation method comprises the following steps: the preparation was as described in reference example 1. EXAMPLE 3 preparation of ambroxol hydrochloride sustained-release particles
The preparation method comprises the following steps: the preparation was as described in reference example 1. EXAMPLE 4 preparation of ambroxol hydrochloride sustained-release particles
The preparation method comprises the following steps: the preparation was as described in reference example 1. EXAMPLE 5 preparation of ambroxol hydrochloride sustained-release particles
The preparation method comprises the following steps: the preparation was as described in reference example 1. EXAMPLE 6 preparation of ambroxol hydrochloride sustained-release particles
The preparation method comprises the following steps: the preparation was as described in reference example 1. EXAMPLE 7 preparation of ambroxol hydrochloride sustained-release particles
The preparation method comprises the following steps: the preparation was as described in reference example 1.
Comparative example 1 preparation of ambroxol hydrochloride sustained-release particles
The preparation method comprises the following steps: adding appropriate amount of water into hydroxypropyl-beta-cyclodextrin, grinding, adding correctant (stevioside, sucralose, strawberry essence) and ambroxol hydrochloride, grinding, mixing, drying at low temperature, washing with absolute ethanol, and drying to obtain clathrate; adding sodium alginate, chitosan, and binder (low substituted hydroxypropyl cellulose, polyvinylpyrrolidone) in the amount of the prescription, mixing, granulating to obtain granule containing medicine; adding water into the sustained release material (sodium carboxymethyl cellulose, acrylic resin) and pore-forming agent (lactose) with the prescription amount to prepare sustained release coating liquid, spraying the sustained release coating liquid on the surfaces of drug-containing particles, and drying to obtain ambroxol hydrochloride sustained release particles.
Comparative example 2 preparation of ambroxol hydrochloride sustained-release particles
The preparation method comprises the following steps: adding a proper amount of water into hydroxypropyl-beta-cyclodextrin with a prescription amount, grinding uniformly, adding ambroxol hydrochloride with a prescription amount, grinding uniformly, drying at low temperature, washing with absolute ethyl alcohol, and drying to obtain an inclusion compound; mixing sodium alginate and chitosan in prescribed amount, heating to molten state, adding clathrate into molten sodium alginate-chitosan liquid, mixing, and drying to obtain medicated core; adding water into sustained release material (sodium carboxymethylcellulose, acrylic acid resin) and pore-forming agent (lactose) to obtain sustained release coating liquid, spraying on the surface of the drug core, drying, adding adhesive (low substituted hydroxypropyl cellulose and polyvinylpyrrolidone), granulating, and drying to obtain ambroxol hydrochloride sustained release granule.
Comparative example 3 preparation of ambroxol hydrochloride sustained-release particles
The preparation method comprises the following steps: mixing sodium alginate and chitosan, heating to molten state, adding correctant (stevioside, sucralose, strawberry essence) and ambroxol hydrochloride into molten liquid of sodium alginate and chitosan, mixing, and drying to obtain medicated core; adding water into sustained release material (sodium carboxymethylcellulose, acrylic acid resin) and pore-forming agent (lactose) to obtain sustained release coating liquid, spraying on the surface of the drug core, drying, adding adhesive (low substituted hydroxypropyl cellulose and polyvinylpyrrolidone), granulating, and drying to obtain ambroxol hydrochloride sustained release granule.
Comparative example 4 preparation of ambroxol hydrochloride sustained-release particles
The preparation method comprises the following steps: adding appropriate amount of water into hydroxypropyl-beta-cyclodextrin, grinding, adding correctant (stevioside, sucralose, strawberry essence), grinding, mixing, adding ambroxol hydrochloride, grinding, mixing, drying at low temperature, washing with absolute ethanol, and drying to obtain clathrate; adding water into the slow release material (sodium carboxymethyl cellulose, acrylic resin) and pore-forming agent (lactose) with a prescription amount to prepare slow release coating liquid, spraying the slow release coating liquid on the surface of an inclusion compound, drying, adding the adhesive (low-substituted hydroxypropyl cellulose and polyvinylpyrrolidone) with a prescription amount, granulating, and drying to obtain ambroxol hydrochloride slow release particles.
Comparative example 5 preparation of ambroxol hydrochloride sustained-release particles
The preparation method comprises the following steps: the preparation was as described in reference example 1.
Experiment one, stability investigation of ambroxol hydrochloride slow release particles
The ambroxol hydrochloride sustained release particles obtained in example 1, example 2, example 6, example 7 and comparative examples 1 to 5 of the present application were subjected to an acceleration test to examine the stability, and the results are shown in table 1 below.
TABLE 1 stability test results of ambroxol hydrochloride sustained release particles
Investigation of dissolution curve of ambroxol hydrochloride slow-release particles in experiment II
The results of examining the cumulative release of ambroxol hydrochloride sustained release particles obtained in example 1, example 2, example 6, example 7 and comparative examples 1 to 5 according to the present application at different time points in a hydrochloric acid buffer solution of pH1.2 and an acetic acid buffer solution of pH4.3 are shown in Table 2 below.
TABLE 2 cumulative Release of ambroxol hydrochloride particles in dissolution Medium at pH1.2
TABLE 2 cumulative Release of ambroxol hydrochloride particles in dissolution Medium at pH1.2

Claims (10)

1. The ambroxol hydrochloride sustained-release particles are characterized by comprising the following components:
ambroxol hydrochloride 20-50 parts
6-30 parts of flavoring agent
Cyclodextrin 60-100 parts
50-100 parts of sodium alginate
30-80 parts of chitosan
10-80 parts of slow-release material
10-50 parts of pore-forming agent
3-20 parts of adhesive;
the preparation method of the ambroxol hydrochloride sustained-release particles comprises the following steps:
step A, adding a flavoring agent into cyclodextrin for grinding, then adding ambroxol hydrochloride, grinding, drying, and washing with an organic solvent to obtain an inclusion compound for later use;
b, adding the inclusion compound obtained in the step A into a sodium alginate-chitosan solution in a molten state, and drying to obtain a medicine core for standby;
and C, preparing a slow-release coating liquid from the slow-release material and Kong Jijia ethanol, spraying the slow-release coating liquid on the surface of the drug core obtained in the step B, drying, adding an adhesive, and granulating to obtain ambroxol hydrochloride slow-release particles.
2. The ambroxol hydrochloride sustained release granule according to claim 1, wherein the ambroxol hydrochloride sustained release granule comprises the following components:
ambroxol hydrochloride 20-50 parts
12-23 parts of flavoring agent
Cyclodextrin 65-80 parts
60-80 parts of sodium alginate
Chitosan 50-60 parts
30-50 parts of slow release material
20-35 parts of pore-forming agent
9-14 parts of adhesive.
3. Ambroxol hydrochloride slow release granule according to claim 2, wherein the flavouring agent is a combination of one or more of stevioside, aspartame, cyclamate, sucralose, xylitol, peppermint essence, strawberry essence, lemon essence, cantaloupe essence and vanillin; preferably, the flavoring agent consists of 2-10 parts of stevioside, 1-8 parts of sucralose and 3-12 parts of strawberry essence.
4. The ambroxol hydrochloride sustained-release granule according to claim 3, wherein the flavoring agent comprises 4-8 parts of stevioside, 3-5 parts of sucralose and 5-10 parts of strawberry essence.
5. The ambroxol hydrochloride sustained-release granule according to claim 2, wherein the sustained-release material is one or more of sodium carboxymethyl cellulose, methylcellulose, hypromellose, povidone, and acrylic resin.
6. The ambroxol hydrochloride sustained-release granule according to claim 5, wherein the sustained-release material consists of 2-35 parts of sodium carboxymethylcellulose and 8-45 parts of acrylic resin.
7. The ambroxol hydrochloride sustained-release granule according to claim 6, wherein the sustained-release material consists of 14-23 parts of sodium carboxymethylcellulose and 16-27 parts of acrylic resin.
8. Ambroxol hydrochloride slow release granule according to claim 2, wherein the porogenic agent is selected from one or more of lactose, mannitol, sucrose, xylitol; preferably, the pore-forming agent is lactose.
9. The ambroxol hydrochloride sustained release granule according to claim 8, wherein the binder is selected from one or more of starch slurry, maltose syrup, methylcellulose, sodium carboxymethylcellulose, low-substituted hydroxypropyl cellulose, hydroxypropyl methylcellulose, ethylcellulose, polyvinylpyrrolidone; preferably, the adhesive consists of 1-12 parts of low-substituted hydroxypropyl cellulose and 2-8 parts of polyvinylpyrrolidone.
10. Ambroxol hydrochloride slow release granule according to claim 9, characterized in that the binder consists of 5-8 parts of low substituted hydroxypropyl cellulose and 4-6 parts of polyvinylpyrrolidone.
CN202310648680.7A 2023-06-02 2023-06-02 Ambroxol hydrochloride sustained-release particles and preparation method thereof Pending CN116637088A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202310648680.7A CN116637088A (en) 2023-06-02 2023-06-02 Ambroxol hydrochloride sustained-release particles and preparation method thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202310648680.7A CN116637088A (en) 2023-06-02 2023-06-02 Ambroxol hydrochloride sustained-release particles and preparation method thereof

Publications (1)

Publication Number Publication Date
CN116637088A true CN116637088A (en) 2023-08-25

Family

ID=87639696

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202310648680.7A Pending CN116637088A (en) 2023-06-02 2023-06-02 Ambroxol hydrochloride sustained-release particles and preparation method thereof

Country Status (1)

Country Link
CN (1) CN116637088A (en)

Similar Documents

Publication Publication Date Title
ES2347968T3 (en) SOLID PREPARATION THAT DISAPPEARS RAPIDLY.
PT97369B (en) METHOD FOR PREPARING PHARMACEUTICAL FORMULATIONS IN WHICH THE FLAVOR OF THE MEDICINE AND DISFORCED BY MEANS OF COATING OF THE MEDICINE WITH A POLYMERIC MEMBRANE
KR101458772B1 (en) PHARMACEUTICAL SUSPENSION CONTAINING PHENYLEPHINPRES AND PROCESS FOR PRODUCING THE
EP1446126B1 (en) Coated particulate cefuroxime axetil compositions
CN1965836B (en) Oral solid formulation and its preparation method
CN102961365A (en) Terbutaline sulfate oral instant film and preparation method thereof
CN116637088A (en) Ambroxol hydrochloride sustained-release particles and preparation method thereof
CN116098864B (en) Linaclotide dry suspension and preparation method thereof
CN112353802A (en) Vonola fumarate taste masking composition and application thereof
CN105581985A (en) Andrographolide dry suspension prepared by fusion spraying and preparation method thereof
CN116392451A (en) Celecoxib tablet and preparation method thereof
CN115737552A (en) Ambroxol hydrochloride oral solution and preparation method thereof
CN104622825A (en) Azithromycin dispersible tablet
CN105581986B (en) A kind of andrographolide dry suspensoid agent and preparation method thereof
CN111437256A (en) Riluzole sustained-release oral suspension
JP6590436B1 (en) Solid formulation with excellent stability
CN112137974B (en) Roxithromycin dispersible tablet and preparation method thereof
CN104490790A (en) Cefuroxime axetil solid dispersion-coated composition and preparation method thereof
CN102573796B (en) Oral liquid preparation containing salbutamol and guaifenesin
CN118078758A (en) Andrographolide anhydrous swallowing granules and preparation method thereof
CN112236146B (en) Solid dosage form with excellent stability
CN118286179A (en) Tilmicosin premix particles and mechanical preparation method thereof
CN112516259A (en) Pharmaceutical composition for treating pneumonia and preparation method thereof
CN118717657A (en) Oral drops containing solimamide hydrochloride and preparation method thereof
CN114432278A (en) A kind of dihydromyricetin quick-acting hangover mouth dissolving agent and preparation method and application thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination